CONTACT INFORMATIONBIOGRAPHYCREDENTIALSAWARDSCLINICAL TRIALSPUBLICATIONSREVIEWSKevin Charles Bylund, M.D.Contact InformationPhone NumbersAppointment: (585) 275-2171Appointment: (585) 475-8700Fax: (585) 341-8469Fax: (585) 275-1531A member of the University of Rochester Medical Faculty GroupgroupAn Accountable Health PartnerassignmentAccepting New PatientsLocations1000 South AveHighland HospitalRochester, NY 14640James P. Wilmot Cancer Center601 Elmwood AveRochester, NY 14642Faculty AppointmentsAssociate Professor - Department of Radiation Oncology (SMD) Patient Care SettingsCancer, Radiation OncologyBiographyWhile in training, I found great fulfillment in caring for patients with cancer, seeing their strength and resolve and trying to match this in my determination to give them the best possible treatment. I was particularly attracted to radiation oncology due to my background in physics and the multitude of options radiation provides to treat patients with cancer. I have special interests in brachytherapy (low-dose and high-dose rates), as well as the protection of normal tissue during radiation therapy. Since I believe all patients have unique stories to tell, my goal is to understand their individual stories – and then to discuss and tailor their radiation and cancer care. I love my work and feel privileged to support patients during the very difficult – and often rewarding – time of cancer treatment and follow-up. Conditions I Treat - Genitourinary cancers (prostate, bladder, kidney, testicular, etc.) - Gynecologic cancers (endometrial, cervical, etc.) - General radiation oncologyCredentialsSpecialtiesEducation2008MD | University of Rochester School of Medicine/DentistryPost-doctoral Training & Residency07/01/2009 - 06/30/2013Residency in Radiation Oncology at University of Rochester Medical Center07/01/2008 - 06/30/2009Internship in Internal Medicine at St. Louis University School of Medicine/Medical CenterAwards2015Educator of the YearSponsor: Association of Residents in Radiation Oncology2012RSNA Roentgen Resident/Fellow Research AwardSponsor: University of RochesterLocation: Rochester, NY2008RSNA Roentgen Resident/Fellow Research AwardSponsor: University of IowaLocation: Iowa City, IAVIEW ALL expand_moreClinical TrialsParallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)Lead Researcher: Kevin Charles Bylund This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score. View Study Details PublicationsJournal Articles2022Kerns SL; Amidon Morlang A; Lee SM; Peterson DR; Marples B; Zhang H; Bylund K; Rosenzweig D; Hall W; De Ruyck K; Rosenstein BS; Stock RG; Gómez-Caamaño A; Vega A; Sosa-Fajardo P; Taboada-Valladares B; Aguado-Barrera ME; Parker C; Veldeman L; Fonteyne V; Bultijnck R; Talbot CJ; Symonds RP; Johnson K; Rattay T; Webb A; Lambrecht M; de Ruysscher D; Vanneste B; Choudhury A; Elliott RM; Sperk E; Herskind C; Veldwijk MR; Rancati T; Avuzzi B; Valdagni R; Azria D; Farcy Jacquet MP; Chang-Claude J; et al. "Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer". Radiother Oncol. 2022; 168: 75-82.2021Singh DP; Aujla K; Nead M; Bylund K. "Radiologically occult lung cancer curatively treated with high-dose rate endobronchial brachytherapy". J Clin Imaging Sci. 2021; 11: 45.2020Ryan Wolf J; Gewandter JS; Bautista J; Heckler CE; Strasser J; Dyk P; Anderson T; Gross H; Speer T; Dolohanty L; Bylund K; Pentland AP; Morrow GR. "Utility of topical agents for radiation dermatitis and pain: a randomized clinical trial". Support Care Cancer. 2020; 28(7): 3303-3311.Books & Chapters2016 Chapter Title: 7-Benzylidine-7-Dehydronaltrexone Book Title: Reference Module in Biomedical Sciences Author List: Bylund DB; Bylund K Published By: Elsevier 20162015 Chapter Title: Testicular Cancer Book Title: Reference Module in Biomedical Sciences Author List: Bylund KC Published By: Elsevier 20152015 Chapter Title: Difenoxin Book Title: Reference Module in Biomedical Sciences Author List: Bylund DB; Bylund K Published By: Elsevier 2015VIEW ALL PUBLICATIONSReviewsAt URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.